Source link : https://www.newshealth.biz/health-news/a-win-for-molecularly-guided-therapy-for-cancer-of-unknown-primary/
Patients with unfavorable cancer of unknown primary (CUP) lived significantly longer without disease progression when they received molecularly guided therapy (MGT) instead of chemotherapy, according to a randomized trial. Median progression-free survival (PFS) improved from 4.4 months to 6.1 months with treatment selected on the basis of comprehensive genomic profiling (CGP). In the subgroup of […]
Author : News Health
Publish date : 2024-08-14 20:27:28
Copyright for syndicated content belongs to the linked Source.
Categories